APGE Apogee Therapeutics, Inc.
APGE Apogee Therapeutics, Inc.
Healthcare · Biotechnology
No longer tracked since 2026-09-04 — left the market.
Market read
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Decision history
1 scored call · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Apogee Therapeutics furnished its earnings release to the SEC on August 10, 2026 (8-K, Item 2.02) and filed its 10-Q for the quarter ended June 30, 2026 the same day. No figures from these filings are recorded here.
full note →Against street estimates
How APGE's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
APGE research tape
48 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.